Targeting Cancer Survival Genes in Solid Tumors

About this episode

Robert Schickel discusses Nuago's innovative approach to targeting cancer survival genes in solid tumors.

Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs out, leading to relapse and poor survival in indications such as liver, ovarian, and prostate cancer. Nuago is developing single-construct short RNAs that simultaneously silence many survival genes in cancer cells to achieve durable tumor cell killing with minimal toxicity to normal tissue. Nuago CEO Robert Schickel discusses the biology behind toxic RNA seeds and tumor-suppressive microRNAs; the company’s lead programs in liver, ovarian, and prostate cancer; and the implications if its cancer-agnostic RNA platform can live up to its preclinical promise.

People in this episode

Guest: Robert Schickel

Topics covered

• cancer therapy
• RNA technology
• tumor genetics
• oncology
• drug resistance

Keywords

• cancer
• survival genes
• short RNAs
• tumor cell killing
• microRNAs

Mentioned in this episode

Organizations: Nuago, Levine Media Group

Places: liver, ovarian, prostate

More episodes of The Bio Report

• Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · June 10, 2026 · 28 min
• Rewriting the Rules of Antibody Drug Design · June 3, 2026 · 38 min
• Mapping Cellular Stress Biology to Tackle Undruggable Targets · May 27, 2026 · 30 min
• Turning Abandoned Drugs into Breakthroughs · May 20, 2026 · 31 min
• Addressing Treatment Gaps in Gout · May 6, 2026 · 37 min
• An Off-the-Shelf Cell Therapy to Calm Cytokine Storms · April 29, 2026 · 28 min